New High-Efficacy Malaria Vaccine Launched in Cote d’Ivoire

Summary: The R21/Matrix-M malaria vaccine, developed by the University of Oxford and the Serum Institute of India with Novavax's Matrix-M adjuvant technology, was recently launched in Cote d’Ivoire, marking a significant step in the global fight against malaria. This high-efficacy, cost-effective vaccine has received WHO approval and aims to vaccinate 250,000 children in Cote d’Ivoire initially. With 25 million doses already produced and plans to manufacture 100 million annually, the vaccine's rollout is expected to significantly reduce malaria mortality, especially among young children. The Serum Institute of India, the world's largest vaccine manufacturer, plays a crucial role in this effort, furthering its legacy of mass-produ